Scaling/Widening of AUC [Regulatives / Guidelines]

posted by Loky do – Egypt, 2021-02-24 14:13 (1154 d 00:22 ago) – Posting: # 22227
Views: 2,716

Dears
Also Regarding AUC widening, is it applicable in both partially and fully replicate designs or fully replicate design only as FDA referred to the published book chapter for RSABE for AUC and Cmax in fda draft guidance for progesterone? So could we apply it in general or it’s not applicable?

Complete thread:

UA Flag
Activity
 Admin contact
22,990 posts in 4,826 threads, 1,647 registered users;
70 visitors (1 registered, 69 guests [including 9 identified bots]).
Forum time: 15:36 CEST (Europe/Vienna)

If you don’t like something change it;
if you can’t change it, change the way you think about it.    Mary Engelbreit

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5